Please ensure Javascript is enabled for purposes of website accessibility

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday

By Cory Renauer – Oct 14, 2021 at 11:20AM

Key Points

  • An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.
  • Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.
  • The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.

What happened

Shares of NRx Pharmaceuticals (NRXP 11.58%) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.  

So what 

This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.

Man reading financial pages in a newspaper.

Image source: Getty Images.

The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.

Now what

Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.

Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.

In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NRx Pharmaceuticals, Inc. Stock Quote
NRx Pharmaceuticals, Inc.
NRXP
$1.39 (11.58%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.